Abstract
Background The COVID-19 pandemic has had a disproportionate impact upon older people. Frailty is being used to further refine the risk of poor outcomes in hospitalised older people. But studies to date on COVID related outcomes using frailty scales have reported inconsistent findings. We plan a retrospective cohort study using national data sources across England. The objectives are:
To determine if there is there an association between COVID-19 infection (virus identified), frailty risk (measured using the Hospital Frailty Risk Score - HFRS) and all-cause mortality.
To evaluate the association between HFRS in people with COVID-19 infection (virus identified), and the following secondary outcomes: hospital length of stay, critical care (entry to critical care, critical care length of stay and deaths in or following a critical care stay).
To determine if there is there an association between COVID-19 infection (virus identified), frailty risk (measured using the HFRS) and costs captured using Healthcare Resource Group tariffs.
Methods This will be a retrospective cohort study using the NHS England Secondary Uses Service (SUS) electronic database, which records hospital activity and outcomes for all patients admitted to National Health Service hospitals in England. The analyses will use data relating to the index hospital presentation, this being the individual’s first emergency presentation during the study period for which they received a COVID-19 test. The primary and secondary outcomes will be constructed for the index admission. The analyses will control for differences in individual characteristics, using a set of risk adjusters including frailty, age, sex, ethnicity, deprivation, Charlson Comorbidity Index, number of previous admissions, number of (surgical) procedures, Ambulatory Care Sensitive Conditions (ACSCs) and COVID-19 status.
Results Baseline characteristics will be reported using descriptive statistics. Mortality will be described using survival analysis, displayed as Kaplan Meier plots. A Cox proportional hazards model using robust standard errors to account for multiple observations (arising from readmissions) of the same individual will be fitted. The analyses will control for differences in individual characteristics, using a set of risk adjusters including frailty (Hospital Frailty Risk Score (HFRS)), age, sex, ethnicity, deprivation, Charlson Comorbidity Index, number of previous admissions, number of (surgical) procedures, Ambulatory Care Sensitive Conditions (ACSCs) and COVID-19 status (ICD-10 codes). Adjusted and unadjusted hazard ratios will be used to compare the rate of death for those with and without confirmed COVID-19, at different HFRS levels. We will test for an interaction between COVID-19 status and HFRS. A logit model will be implemented to analyse the secondary outcomes of admission to critical care mortality at 30 days, and mortality in critical care. For length of stay in hospital and in critical care, Poisson or negative binomial regression models will be fitted depending upon the dispersion.
Impact The results of the study will inform clinicians about how best to use the frailty concept when assessing older people with COVID-19, for example in national guidelines that the study team have been involved in preparing: https://www.criticalcarenice.org.uk/.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Fulham Research Ethics Committee (part of the UK Health Regulatory Authority) reviewed the application on and issued a Favourable Opinion (reference 289267). The University of Leicester acted as study sponsor (reference 0804 COVID & Frailty).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
rob.konstant-hambling{at}nhs.net, towhid.imam{at}nhs.net, rhiannon.owen{at}le.ac.uk, A.Street{at}lse.ac.uk, L.Maynou-Pujolras{at}lse.ac.uk, suzanne.arkill{at}nhs.net, spc3{at}le.ac.uk
Data Availability
If anyone wanted to replicate the analyses, they would have to request access from the data owner/controller (NHS England). The study protocol will be made available, as will the Stata codes for the analysis.
